Vyas Tungaturti is a seasoned M&A operator and advisor specializing in large-scale mergers, acquisitions, and private equity due diligence. His experience spans integration and divestiture office leadership, complex cross-border transactions, and the application of AI and machine learning to deal execution. Founder of CorpDev.Org and builder of Kai, an AI due-diligence platform for deal teams, Vyas writes on deal intelligence, value creation, and how AI is reshaping M&A and PE workflows.
TL;DR
Prague-based Flowpay announced its acquisition of Berlin's Tapline on March 3, 2026, for undisclosed financial terms. The deal integrates Flowpay's traditional SME lending with Tapline's...
TL;DR
A consortium led by EQT and Global Infrastructure Partners (GIP) will take The AES Corporation private in an all-cash deal with an enterprise value of approximately $33.4 billion. The $15.00...
TL;DR
Telefónica Executive Chairman Marc Murtra is advocating for immediate regulatory relief on mergers in the European telecommunications sector to enable consolidation, which he argues is...
TL;DR
Medline Industries Inc.'s private equity sponsors, including Blackstone, Carlyle, and Hellman & Friedman, are divesting approximately 75 million Class A shares in a secondary offering...
TL;DR
Oaktree Capital Management is exploring a London IPO for its UK wealth solutions provider, Utmost Group, at a potential valuation of £2.5 billion ($3.3 billion). The private equity firm has...
TL;DR
Anthropic acquired Vercept, an AI startup specializing in agentic task automation, with the deal announced on February 26, 2026. While financial terms remain undisclosed, Anthropic secured...
TL;DR
Netflix has withdrawn its $83 billion offer for Warner Bros. Discovery's studio and streaming assets, clearing the path for Paramount Skydance's superior $111 billion bid to acquire the entire...
TL;DR
Sealed Air shareholders approved the company's acquisition by private equity firm Clayton, Dubilier & Rice (CD&R) for an enterprise value of approximately $5 billion. The all-cash deal...
TL;DR
Novo Nordisk entered a partnership with Vivtex Corp. valued at up to $2.1 billion to develop oral medicines for obesity and diabetes. The deal leverages Vivtex's proprietary drug delivery...
TL;DR
CalPERS, managing over $500 billion, maintains private equity as a core investment, targeting 13-15% allocation even after transitioning to a Third-Party Administrator (TPA) model in 2025. CEO...
